These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 25652561)
61. Two UK Government proposals bearing on drug safety. Griffin JP Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053 [No Abstract] [Full Text] [Related]
62. National adverse drug reaction reporting. 1984-1989. Faich GA Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669 [TBL] [Abstract][Full Text] [Related]
63. Sequential surveillance for drug safety in a regulatory environment. Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168 [No Abstract] [Full Text] [Related]
64. Adverse drug reactions in Canada. Hematologic reactions to sterol and sterolin-containing products. Can Fam Physician; 2004 Aug; 50():1115-6. PubMed ID: 15455811 [No Abstract] [Full Text] [Related]
65. An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence. Xiao C; Li Y; Baytas IM; Zhou J; Wang F Sci Rep; 2018 Jan; 8(1):1806. PubMed ID: 29379048 [TBL] [Abstract][Full Text] [Related]
66. Postmarketing surveillance and reporting of adverse drug events. Baer RK S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975 [No Abstract] [Full Text] [Related]
68. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. Stobaugh DJ; Deepak P; Ehrenpreis ED J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730 [TBL] [Abstract][Full Text] [Related]
69. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration. Ma P; Marinovic I; Karaca-Mandic P JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395 [No Abstract] [Full Text] [Related]
70. Reporting of adverse drug reactions by nurses. Morrison-Griffiths S; Walley TJ; Park BK; Breckenridge AM; Pirmohamed M Lancet; 2003 Apr; 361(9366):1347-8. PubMed ID: 12711472 [TBL] [Abstract][Full Text] [Related]
71. The state of adverse event reporting and signal generation of dietary supplements in Korea. Park KS; Kwon O Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608 [TBL] [Abstract][Full Text] [Related]
72. Comment on: "Adverse drug reaction reporting by patients: an overview of fifty countries". Ahmad SR Drug Saf; 2015 Jan; 38(1):109-10. PubMed ID: 25414075 [No Abstract] [Full Text] [Related]
73. Vaccine adverse event reporting: the importance of follow-up. Varricchio F Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700 [No Abstract] [Full Text] [Related]
79. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Asturias EJ; Contreras-Roldan IL; Ram M; Garcia-Melgar AJ; Morales-Oquendo V; Hartman K; Rauscher M; Moulton LH; Halsey NA Vaccine; 2013 Dec; 31(49):5909-14. PubMed ID: 24055354 [TBL] [Abstract][Full Text] [Related]
80. Adverse drug reaction reporting systems: the United Kingdom and the United States. Scott HD; Thacher A; Rosenbaum SE; Waters WJ; Green M R I Med J (1976); 1988 May; 71(5):179-84. PubMed ID: 3387803 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]